SCHEMBL30714675

SCHEMBL30714675

Cc1ncsc1COc1ccc2nn(C)c(C(=O)NC3CCN(CCO)C3=O)c2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.35
HPGDS O60760 1/20 0.34
ACACB O00763 1/20 0.32
HTR3A P46098 1/20 0.31
XIAP P98170 1/20 0.31
BIRC2 Q13490 1/20 0.31
FKBP5 Q13451 1/20 0.31
KDM4E B2RXH2 2/20 0.31
MEN1 O00255 2/20 0.31
ALDH1A1 P00352 2/20 0.31
KMT2A Q03164 2/20 0.31
PDE7A Q13946 1/20 0.31
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31
RAB9A P51151 1/20 0.31
BLM P54132 1/20 0.31
ATM Q13315 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714565 0.85 HTR3A (0.44) HTR3AXIAPKDM4EALDH1A1RIPK1
SCHEMBL30714705 0.83 MET (0.40) HPGDSHTR3AKDM4EMEN1ALDH1A1
SCHEMBL30714689 0.83 HPGDS (0.35) SCN9AHPGDSHTR3AKDM4EMEN1
SCHEMBL30714573 0.83 MET (0.40) HPGDSHTR3AKDM4EMEN1ALDH1A1
SCHEMBL30714733 0.83 HPGDS (0.41) HPGDSACACBNPC1RAB9AHPGD
SCHEMBL24484334 0.83 GAA (0.38) KDM4EMEN1ALDH1A1KMT2APOLB
SCHEMBL30656139 0.83 ESR1 (0.34) SCN9AHPGDSACACBXIAPBIRC2
SCHEMBL30656106 0.83 ESR1 (0.34) SCN9AHPGDSACACBXIAPBIRC2
SCHEMBL30714585 0.83 SLC6A5 (0.42) HTR3AKDM4EALDH1A1HPGD
SCHEMBL30714614 0.82 GUCY1B2 (0.40) HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 SCN9A 518/4885HPGDS 671/4885ACACB 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.